Literature DB >> 26488173

General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan.

Masatoshi Kudo1, Masayuki Kitano, Toshiharu Sakurai, Naoshi Nishida.   

Abstract

This review outlines the significance of establishing general rules, a nationwide follow-up survey, and clinical practice guidelines for liver cancer in Japan. The general rules are an essential part of hepatocellular carcinoma (HCC) treatment, enabling a 'common language' to be used in daily clinical practice and for the nationwide follow-up survey. The Japanese General Rules for the Clinical and Pathological Study of Primary Liver Cancer, which provide detailed descriptions of HCC, are excellent and are unique to Japan. Items in the General Rules for the Clinical and Pathological Study of Primary Liver Cancer are used substantially in another important project, the Nationwide Follow-Up Survey of Primary Liver Cancer, which has been rigorously undertaken with great effort by the Liver Cancer Study Group of Japan biannually since 1969. Both evidence-based and consensus-based treatment algorithms for HCC are used to complement each other in clinical practice in Japan.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26488173     DOI: 10.1159/000439101

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  98 in total

1.  Efficacy and prognostic factors of transarterial embolization as initial treatment for spontaneously ruptured hepatocellular carcinoma: a single-center retrospective analysis in 57 patients.

Authors:  Chun Zhou; Qing-Quan Zu; Bin Wang; Chun-Gao Zhou; Hai-Bin Shi; Sheng Liu
Journal:  Jpn J Radiol       Date:  2018-12-03       Impact factor: 2.374

2.  Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  Yukinori Imai; Taku Chikayama; Manabu Nakazawa; Kazuhiro Watanabe; Satsuki Ando; Yoshie Mizuno; Kiyoko Yoshino; Kayoko Sugawara; Kazuhiro Hamaoka; Kenji Fujimori; Mie Inao; Nobuaki Nakayama; Masashi Oka; Sumiko Nagoshi; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2011-10-06       Impact factor: 7.527

Review 3.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 4.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

5.  Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-08-24       Impact factor: 11.740

Review 6.  Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016.

Authors:  Stephen L Chan; Charing C N Chong; Anthony W H Chan; Darren M C Poon; Kenneth S H Chok
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

7.  Assessment of the response of hepatocellular carcinoma to interventional radiology treatments.

Authors:  Francesca Patella; Filippo Pesapane; Enrico Fumarola; Stefania Zannoni; Pietro Brambillasca; Ilaria Emili; Guido Costa; Victoria Anderson; Elliot B Levy; Gianpaolo Carrafiello; Bradford J Wood
Journal:  Future Oncol       Date:  2019-05-02       Impact factor: 3.404

8.  Two patterns of contrast-enhanced ultrasonography with Sonazoid® in spontaneous rupture of hepatocellular carcinoma: a report of four cases.

Authors:  Takaaki Sugihara; Masahiko Koda; Toshiaki Okamoto; Kenichi Miyoshi; Tomomitsu Matono; Hajime Isomoto
Journal:  J Med Ultrason (2001)       Date:  2017-08-16       Impact factor: 1.314

9.  Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.

Authors:  Yasunari Hiramine; Hirofumi Uto; Seiichi Mawatari; Shuji Kanmura; Yasushi Imamura; Takuya Hiwaki; Akiko Saishoji; Manei Oku; Koichi Tokushige; Shigeho Maenohara; Akio Ido
Journal:  J Gastroenterol       Date:  2020-09-21       Impact factor: 7.527

10.  Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis.

Authors:  Keisuke Arai; Takumi Fukumoto; Masahiro Kido; Motofumi Tanaka; Kaori Kuramitsu; Hisoka Kinoshita; Shohei Komatsu; Daisuke Tsugawa; Sachio Terai; Taku Matsumoto; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Tetsuo Ajiki; Yonson Ku
Journal:  Surg Today       Date:  2016-07-27       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.